A new policy threatens the stability of federal cannabis regulations, sparking debate over states’ rights and economic impacts.
Story Snapshot
- President Trump signs an executive order to expedite marijuana’s rescheduling to Schedule III.
- DEA process for rescheduling is underway, pending finalization.
- No credible reports confirm fentanyl’s classification as a Weapon of Mass Destruction.
- Industry anticipates significant economic benefits from tax relief and banking access.
Trump’s Executive Order on Marijuana Rescheduling
On December 18, 2025, President Trump signed an executive order mandating the expedited transfer of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move follows an extended review process initiated by the previous administration and aims to facilitate medical access while addressing state and federal regulatory conflicts.
https://www.youtube.com/watch?v=agzymYdk15c
The executive order instructs the Attorney General to prioritize this rescheduling as a means to enhance patient access to full-spectrum CBD products. Despite the progress, marijuana remains classified as Schedule I federally until the DEA finalizes the rulemaking process. This development marks a significant shift in federal cannabis policy, though final implementation details remain uncertain.
Economic and Social Implications
Rescheduling marijuana to Schedule III could end the burdensome §280E tax restrictions, allowing cannabis businesses to claim deductions and significantly improve profitability. This change is expected to open banking opportunities for businesses operating in compliance with state laws, which could boost the industry’s growth and stability. However, the federal illegality of marijuana still poses challenges for full economic relief.
Beyond the immediate economic benefits, the rescheduling is anticipated to support further research into medical marijuana’s uses and benefits. This could catalyze advancements in treatment options for conditions like chronic pain and nausea, aligning with the administration’s stated goals of improving healthcare access and outcomes.
Fentanyl and Misleading Claims
In contrast to the marijuana rescheduling, no credible sources confirm the declaration of fentanyl as a Weapon of Mass Destruction. This claim appears to stem from separate discussions on opioid regulation and has not been substantiated by any official actions or legislative measures. Fentanyl remains a Schedule II substance under current federal law, reflecting its recognized medical uses despite its high abuse potential.
WAPO confirms what I reported earlier with even more: Trump is not only seeking to reschedule weed but he had WEED INDUSTRY EXECS on a phone call to convince Speaker Johnson why it was a good idea
Genuinely ironic to bailout big weed when mounting a fake drug war on Venezuela pic.twitter.com/NIRzap5oOW
— Saagar Enjeti (@esaagar) December 11, 2025
The confusion regarding fentanyl’s status underscores the complexities of drug policy and the potential for misinformation in public discourse. Stakeholders must navigate these challenges carefully to ensure that policy decisions reflect accurate information and balanced priorities.
Sources:
Federal Cannabis Rescheduling Creates New Banking Opportunities
Federal Marijuana Rescheduling
Historic Marijuana Rescheduling to Schedule III: The Football Just Moved Closer to the End Zone
